HomeIPSEF • OTCMKTS
Ipsen SA
$125.37
Nov 15, 12:19:21 AM GMT-5 · USD · OTCMKTS · Disclaimer
StockUS listed security
Previous close
$125.37
Year range
$108.75 - $132.50
Market cap
9.52B EUR
Avg Volume
5.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
CDP Climate Change Score
B
In the news
Financials
Income Statement
Revenue
Net income
(EUR)Jun 2024Y/Y change
Revenue
875.90M7.93%
Operating expense
557.05M8.31%
Net income
116.00M18.85%
Net profit margin
13.2410.06%
Earnings per share
——
EBITDA
240.85M0.31%
Effective tax rate
16.30%—
Total assets
Total liabilities
(EUR)Jun 2024Y/Y change
Cash and short-term investments
485.40M17.42%
Total assets
6.55B7.50%
Total liabilities
2.50B-6.93%
Total equity
4.05B—
Shares outstanding
82.86M—
Price to book
2.57—
Return on assets
6.13%—
Return on capital
8.85%—
Net change in cash
(EUR)Jun 2024Y/Y change
Net income
116.00M18.85%
Cash from operations
233.00M8.52%
Cash from investing
-99.55M79.81%
Cash from financing
-159.10M-51.45%
Net change in cash
-26.00M93.10%
Free cash flow
15.01M-89.78%
About
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
Founded
1929
Website
Employees
5,325
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
Search
Clear search
Close search
Google apps
Main menu